Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatment Burden and Chronic Illness: Who is at Most Risk?
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
The "poison chair" treatment for multiple sclerosis.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Drugs@FDA
Rare onset symptoms in multiple sclerosis.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Central nervous system neuroinflammatory disorders in Asian/Pacific regions.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Recent insights into the mechanism of action of glatiramer acetate.
Timing of birth and risk of multiple sclerosis: population based study.
Glial cells as drug targets: What does it take?
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
Voiding Dysfunction in Multiple Sclerosis.
Policy: NIH to balance sex in cell and animal studies.
Autoimmune myelopathies.

Pages